GlassScriptPhysician profile
Obinna Mmagu
NPI 1477965788
$8,627.45
in general payments reported to CMS, 2019-2025
29 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $925 · 2021: $1,052 · 2022: $3,267 · 2023: $1,248 · 2024: $566 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,072.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $2,727.87 | 2020-2025 | Amvuttra |
| Abbott Laboratories | $812.41 | 2019-2025 | Aveir, Gallant, Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $667.23 | 2021-2025 | Inceptiv, Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $550.62 | 2020-2025 | Lifevest |
| Novo Nordisk INC | $411.33 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Medtronic Vascular, INC. | $396.69 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $334.18 | 2019-2024 | Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $328.86 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $309.52 | 2021-2025 | Verquvo |
| Pfizer INC. | $297.89 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.42 | 2021-2025 | Jardiance |
| Boston Scientific Corporation | $226.02 | 2023 | Watchman Access System, Bodyguardian, Lux-Dx Insertable Cardiac Monitor |
| Bridgebio Pharma, INC. | $169.79 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $151.78 | 2024-2025 | Camzyos |
| Cvrx, INC. | $145.00 | 2023 | Barostim Neo System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $124.99 | 2020 | |
| Amgen INC. | $107.58 | 2020-2025 | Repatha |
| Cardiovascular Systems INC. | $106.76 | 2020 | |
| Cardiva Medical, INC. | $84.43 | 2024-2025 | Optowire, Cardiva Vascade 6/7f Vcs |
| Kiniksa Pharmaceuticals, LTD. | $62.79 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $62.50 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $60.25 | 2023-2024 | |
| Arbor Pharmaceuticals, INC. | $56.98 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $34.06 | 2024 | Opsumit |
| Recor Medical INC | $33.83 | 2025 | Paradise Ultrasound Renal Denervation System |
| Daiichi Sankyo INC. | $24.68 | 2023 | Injectafer |
| Heartflow, INC. | $20.17 | 2023 | Ffrct |
| Itamar Medical INC | $18.35 | 2022 | |
| Philips North America LLC | $17.47 | 2024 | (Ck4) Mcot |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Obinna Mmagu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.